Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 9/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 9/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 9/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 9/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 9/20 | 0.43 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20354803 | 1.00 | PRKAB2 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL17850497 | 0.76 | GPR84 (0.51) | SLC6A4 | |
| SCHEMBL30684580 | 0.76 | GPR84 (0.51) | SLC6A4 | |
| SCHEMBL21569505 | 0.75 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL20355068 | 0.74 | GPR84 (0.50) | — | |
| SCHEMBL20339031 | 0.74 | CYP2A6 (0.51) | SLC6A4 | |
| SCHEMBL20354730 | 0.74 | MEN1 (0.47) | — | |
| SCHEMBL20339112 | 0.73 | SLC22A12 (0.40) | SLC6A4 | |
| SCHEMBL21569506 | 0.73 | TRIM24 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL26776418 | 0.72 | PARP15 (0.52) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | PRKAB2 1381/4885PRKAG1 1344/4885PRKAA2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.